Home » Stocks » ABSI

Absci Corporation (ABSI)

Stock Price: $22.89 USD 1.30 (6.02%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $23.99 +1.10 (4.81%) Jul 23, 5:53 PM
Market Cap 2.07B
Revenue (ttm) 5.27M
Net Income (ttm) -47.61M
Shares Out 90.38M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $22.89
Previous Close $21.59
Change ($) 1.30
Change (%) 6.02%
Day's Open 22.00
Day's Range 21.50 - 24.00
Day's Volume 664,306
52-Week Range 20.88 - 24.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

VANCOUVER, Wash., July 21, 2021 (GLOBE NEWSWIRE) -- Absci Corporation (“Absci”), the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, today announced the pr...

2 days ago - GlobeNewsWire

It plans to list on the Nasdaq exchange under the ticker symbol ABSI.

3 weeks ago - The Oregonian

Vancouver biotech company AbSci announced its intention to file for an initial public offering on Wednesday.

3 weeks ago - The Columbian

Absci Corporation has filed to go public with an IPO on the NASDAQ.

3 weeks ago - SEC

About ABSI

Absci was founded with the goal of creating better medicines and helping them reach patients sooner. With our AI-powered Integrated Drug Creation Platform we enable the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. We leverage proprietary synthetic biology technologies and deep learning AI to predict, identify, design, construct, screen, select and scale production of novel biologic drug candidates, and learn from the data we generate. Our goal is to become the partner o... [Read more...]

Industry
Biological Research
IPO Date
Jul 22, 2021
CEO
Sean McClain
Employees
169
Stock Exchange
NASDAQ
Ticker Symbol
ABSI
Full Company Profile

Financial Performance

In 2020, Absci's revenue was $4.78 million, an increase of 132.04% compared to the previous year's $2.06 million. Losses were -$14.35 million, 118.0% more than in 2019.

Financial Statements